Front Desk: 469-391-0070
Bendamustine Chemotherapy: Uses, Dosage, and Treatment Guide
Key Points About Bendamustine Chemotherapy
Bendamustine is a prescription medication used to treat various cancers, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). It works by disrupting the growth of cancer cells, slowing their spread throughout the body. Bendamustine is typically administered through an intravenous (IV) infusion. Always consult your healthcare provider before starting or adjusting your dose. You can also schedule a telemedicine appointment with one of our providers for personalized care.
Names of Bendamustine Medication
US Brand Name: Treanda, Bendeka
Generic Name: Bendamustine
The generic name refers to the active ingredient, while the brand name is assigned by the manufacturer. The generic name is listed in parentheses.
Pharmacologic Category of Bendamustine
Alkylating Agent
Antineoplastic Agent
Bendamustine Dosage and Treatment Schedule
Bendamustine is used to treat several types of cancers in adults. The dosage varies depending on the specific condition being treated. Always follow your doctor’s instructions and consult them before making any changes to your dose. You can also schedule a telemedicine appointment with one of our providers for further guidance.
Bendamustine Dosage for Chronic Lymphocytic Leukemia (CLL)
Initial Dose: 100 mg/m² IV infusion on Days 1 and 2 of a 28-day cycle.
Frequency: Every 28 days.
Duration: Continue until disease progression or unacceptable toxicity.
Bendamustine for Non-Hodgkin Lymphoma (NHL)
Initial Dose: 120 mg/m² IV infusion on Days 1 and 2 of a 21-day cycle.
Frequency: Every 21 days.
Duration: Continue for up to 8 cycles or until disease progression.
Bendamustine Dosage for Multiple Myeloma
Initial Dose: 60 mg/m² IV infusion on Days 1 and 2 of a 28-day cycle.
Frequency: Every 28 days.
Duration: Continue until disease progression or unacceptable toxicity.
Bendamustine for Follicular Lymphoma
Initial Dose: 120 mg/m² IV infusion on Days 1 and 2 of a 21-day cycle.
Frequency: Every 21 days.
Duration: Continue for up to 6 cycles or until disease progression.
Bendamustine Dosage for Mantle Cell Lymphoma
Initial Dose: 90 mg/m² IV infusion on Days 1 and 2 of a 28-day cycle.
Frequency: Every 28 days.
Duration: Continue for up to 6 cycles or until disease progression.
Bendamustine for Hodgkin Lymphoma
Initial Dose: 120 mg/m² IV infusion on Days 1 and 2 of a 21-day cycle.
Frequency: Every 21 days.
Duration: Continue for up to 6 cycles or until disease progression.
Bendamustine Dosage for Acute Myeloid Leukemia (AML)
Initial Dose: 100 mg/m² IV infusion on Days 1 and 2 of a 28-day cycle.
Frequency: Every 28 days.
Duration: Continue until disease progression or unacceptable toxicity.
Bendamustine for Waldenström’s Macroglobulinemia
Initial Dose: 90 mg/m² IV infusion on Days 1 and 2 of a 28-day cycle.
Frequency: Every 28 days.
Duration: Continue for up to 6 cycles or until disease progression.
Bendamustine Dosage for Peripheral T-cell Lymphoma
Initial Dose: 120 mg/m² IV infusion on Days 1 and 2 of a 21-day cycle.
Frequency: Every 21 days.
Duration: Continue for up to 6 cycles or until disease progression.
Bendamustine for B-cell Lymphoma
Initial Dose: 120 mg/m² IV infusion on Days 1 and 2 of a 21-day cycle.
Frequency: Every 21 days.
Duration: Continue for up to 6 cycles or until disease progression.
Dosage Forms and Strengths of Bendamustine
Injection, powder for reconstitution: 25 mg/vial, 100 mg/vial
Injection, solution: 100 mg/4 mL (25 mg/mL)
Bendamustine Infusion Process and Administration Instructions
Bendamustine is administered as an intravenous (IV) infusion, meaning it is delivered directly into a vein. The infusion is typically performed in a healthcare setting, such as a hospital or clinic, under the supervision of a healthcare provider. The infusion process usually takes about 30 to 60 minutes, depending on the dose and the condition being treated. It is important to follow your healthcare provider’s instructions regarding the timing and frequency of your treatments. If you have any concerns about your treatment schedule, you can consult one of our telemedicine providers for further advice.
Contraindications for Bendamustine Chemotherapy
A contraindication is a specific situation or condition where a particular medication should not be used because it may cause harm to the patient. In the case of Bendamustine, there are several situations where it is not recommended due to potential risks.
Severe liver impairment: Bendamustine is processed by the liver, so patients with severe liver disease may not metabolize the drug properly, leading to increased toxicity.
Allergy to Bendamustine or its components: If you have a known allergy to Bendamustine or any of its inactive ingredients, taking the medication could cause a severe allergic reaction, which may be life-threatening.
Severe bone marrow suppression: Bendamustine can lower blood cell counts, so it is contraindicated in patients who already have significantly reduced bone marrow function, as this could lead to life-threatening infections or bleeding.
Active infection: Because Bendamustine can weaken the immune system, it should not be used in patients with active infections, as it may worsen the infection or make it harder for the body to fight it.
Drug to Drug Interactions
Bendamustine can interact with other medications, potentially affecting its effectiveness or increasing the risk of side effects. It’s important to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medicines, and supplements. Below are some medications that may interact with Bendamustine chemotherapy:
CYP1A2 inhibitors: Drugs such as ciprofloxacin (Cipro) and fluvoxamine (Luvox) can increase Bendamustine levels in the blood, which may lead to heightened toxicity.
Immunosuppressants: Medications like tacrolimus (Prograf) and cyclosporine (Neoral) can further suppress the immune system, increasing the risk of infections.
Live vaccines: Vaccines such as the measles, mumps, and rubella (MMR) vaccine or the varicella (chickenpox) vaccine should be avoided, as Bendamustine weakens the immune system, making live vaccines potentially harmful.
Blood thinners: Medications like warfarin (Coumadin) may increase the risk of bleeding when taken with Bendamustine.
Bendamustine in Pregnancy
Is it Safe to Take Bendamustine During Pregnancy?
No, Bendamustine is not considered safe during pregnancy. It can harm an unborn baby, potentially causing birth defects or miscarriage. Classified as a pregnancy category D drug, Bendamustine has shown clear evidence of fetal risk based on human studies. If you are pregnant or planning to become pregnant, discuss alternative treatments with your healthcare provider. If you become pregnant while taking Bendamustine, contact your doctor immediately to discuss your options.
Bendamustine While Breastfeeding
Is it Safe to Take Bendamustine While Breastfeeding?
No, Bendamustine is not recommended while breastfeeding. Although it is unknown whether Bendamustine passes into breast milk, the potential for serious adverse effects in a nursing infant means breastfeeding should be discontinued during treatment and for at least one week after the last dose. If you are breastfeeding or planning to breastfeed, consult your healthcare provider to determine the best course of action.
Estimated Cost of Bendamustine
The cost of Bendamustine can vary depending on your location and pharmacy. Without insurance, the estimated cost of a 30-day supply using a GoodRx coupon ranges from $1,200 to $1,500. Prices may differ, so it’s a good idea to check with your pharmacy or use a discount service like GoodRx to find the best price.
Possible Alternatives to Bendamustine
If Bendamustine is not suitable for you, there are alternative treatments available for the conditions it treats. Always consult your healthcare provider before making any changes to your treatment plan. Below are some alternatives:
Chronic Lymphocytic Leukemia (CLL)
- Other chemotherapy agents, such as fludarabine or chlorambucil
- Targeted therapies like ibrutinib (Imbruvica) or venetoclax (Venclexta)
- Monoclonal antibodies, such as rituximab (Rituxan)
Non-Hodgkin Lymphoma
- R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
- Immunotherapy options like CAR-T cell therapy
- Radiation therapy
Multiple Myeloma
- Proteasome inhibitors like bortezomib (Velcade)
- Immunomodulatory drugs such as lenalidomide (Revlimid)
- Stem cell transplant
Follicular Lymphoma
- Rituximab (Rituxan) alone or in combination with chemotherapy
- Radioimmunotherapy
- Targeted therapies like idelalisib (Zydelig)
Mantle Cell Lymphoma
- Combination chemotherapy regimens like R-CHOP
- Bruton’s tyrosine kinase (BTK) inhibitors, such as ibrutinib (Imbruvica)
- Stem cell transplant
Hodgkin Lymphoma
- ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine)
- Brentuximab vedotin (Adcetris)
- Radiation therapy
Acute Myeloid Leukemia (AML)
- Cytarabine and anthracycline-based chemotherapy
- Targeted therapies like midostaurin (Rydapt) or enasidenib (Idhifa)
- Stem cell transplant
Waldenström’s Macroglobulinemia
- Plasmapheresis to reduce blood viscosity
- Targeted therapies like ibrutinib (Imbruvica)
- Rituximab (Rituxan) in combination with chemotherapy
Peripheral T-cell Lymphoma
- Combination chemotherapy regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
- Pralatrexate (Folotyn)
- Stem cell transplant
B-cell Lymphoma
- R-CHOP regimen
- CAR-T cell therapy
- Radiation therapy
Recent Updates on Bendamustine Research
Recent studies have explored combining Bendamustine with other therapies to improve outcomes in patients with various types of lymphoma. For example, ongoing research is investigating the combination of Bendamustine with novel immunotherapies, such as checkpoint inhibitors, to enhance the immune system’s ability to target cancer cells. Additionally, researchers are studying the use of lower doses of Bendamustine to reduce side effects while maintaining its effectiveness.
As of 2023, clinical trials are also examining Bendamustine’s potential in treating other cancers, such as solid tumors, though these studies are still in early phases. If you are interested in participating in a clinical trial or learning more about the latest research, speak with your healthcare provider or schedule a telemedicine appointment with one of our providers today.
